Bristol-Myers Squibb Company Announces Extension of U.S. Agreement for ABILIFY(R) and Establishment of an Oncology Collaboration with Otsuka America Pharmaceutical, Inc.

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced an agreement with Otsuka Pharmaceutical Co., Ltd. (hereafter, “Otsuka”) to extend the U.S. portion of the companies’ long-standing agreement for the development and commercialization of ABILIFY®(aripiprazole) from the currently scheduled end date of November 2012 until the expected loss of exclusivity in April 2015. In addition, the companies have established an oncology collaboration for two Bristol-Myers Squibb products -- SPRYCEL® (dasatinib) and IXEMPRA® (ixabepilone).

Back to news